Increase of 27-hydroxycholesterol in the airways of patients with COPD: Possible role of 27-hydroxycholesterol in tissue fibrosis

Chest

Volumn 142, Issue 2, 2012, Pages 329-337

  Kikuchi, Takashi ^a   Sugiura, Hisatoshi ^a   Koarai, Akira ^a   Ichikawa, Tomohiro ^a   Minakata, Yoshiaki ^a   Matsunaga, Kazuto ^a   Nakanishi, Masanori ^a   Hirano, Tsunahiko ^a   Akamatsu, Keiichirou ^a   Yanagisawa, Satoru ^a   Furukawa, Kanako ^a   Kawabata, Hiroki ^a   Ichinose, Masakazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; SCLEROPROTEIN; STEROL 27 HYDROXYLASE; TRANSFORMING GROWTH FACTOR BETA1;

AGED; ARTICLE; CELL DIFFERENTIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; FETUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; MYOFIBROBLAST; PERIBRONCHIAL FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPUTUM ANALYSIS; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 84864805188     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2091     Document Type: Article

References (42)

1. Björkhem I. Mechanism of degradation of the steroid side chain in the formation of bile acids. J Lipid Res. 1992;33(4):455-471.
2. Javitt NB. Bile acid synthesis from cholesterol: regulatory and auxiliary pathways. FASEB J. 1994;8(15):1308-1311.
3. Björkhem I. Do oxysterols control cholesterol homeostasis? J Clin Invest. 2002;110(6):725-730.
4. Lemaire-Ewing S, Prunet C, Montange T, et al. Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol Toxicol. 2005;21(2):97-114. (Pubitemid 41253203)
5. Morello F, Saglio E, Noghero A, et al. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis. 2009;207(1):38-44.
6. Rantham Prabhakara JP, Feist G, Thomasson S, Thompson A, Schommer E, Ghribi O. Differential effects of 24-hydroxycholesterol and 27- hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SH-SY5Y cells. J Neurochem. 2008;107(6):1722-1729.
7. Hultén LM, Lindmark H, Diczfalusy U, et al. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J Clin Invest. 1996;97(2):461-468.
8. Heverin M, Bogdanovic N, Lütjohann D, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res. 2004;45(1):186-193. (Pubitemid 38180529)
9. Tomaki M, Sugiura H, Koarai A, et al. Decreased expression of antioxidant enzymes and increased expression of chemokines in COPD lung. Pulm Pharmacol Ther. 2007;20(5):596-605. (Pubitemid 47077652)
10. Sugiura H, Koarai A, Ichikawa T, et al. Increase of 25-hydroxycholesterol in the airways of chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med. 2011;183(1):A2998.
11. Brown AJ, Jessup W. Oxysterols and atherosclerosis. Atherosclerosis. 1999;142(1):1-28. (Pubitemid 28553934)
12. Global strategy for the diagnosis, management and prevention of COPD. GOLD website. http://www.goldcopd.org. 2010. Accessed June 2011.
13. Barnes PJ, Drazen JM, Rennard SI, et al. Asthma and COPD. 2nd ed. San Diego, CA:Academic Press;2009:193-195.
14. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653. (Pubitemid 38787999)
15. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435-459.
16. Barnes PJ. Small airways in COPD. N Engl J Med. 2004;350(26):2635-2637. (Pubitemid 38787995)
17. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med. 2000;162(2 pt 1):701-706. (Pubitemid 30647222)
18. Björkhem I, Andersson O, Diczfalusy U, et al. Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A. 1994;91(18):8592-8596. (Pubitemid 24273710)
19. Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC. Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res. 1994;35(6):1026-1030. (Pubitemid 24181107)
20. Andersson S, Davis DL, Dahlbäck H, Jörnvall H, Russell DW. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 1989;264(14):8222-8229. (Pubitemid 19137311)
21. Babiker A, Andersson O, Lund E, et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J Biol Chem. 1997;272(42):26253-26261. (Pubitemid 27458836)
22. Lund E, Andersson O, Zhang J, et al. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arterioscler Thromb Vasc Biol. 1996;16(2):208-212. (Pubitemid 26056238)
23. Hansson M, Wikvall K, Babiker A. Regulation of sterol 27-hydroxylase in human monocyte-derived macrophages: up-regulation by transforming growth factor beta1. Biochim Biophys Acta. 2005;1687(1-3) :44-51. (Pubitemid 40228984)
24. Hodge SJ, Hodge GL, Reynolds PN, Scicchitano R, Holmes M. Increased production of TGF-beta and apoptosis of T lymphocytes isolated from peripheral blood in COPD. Am J Physiol Lung Cell Mol Physiol. 2003;285(2):L492-L499. (Pubitemid 36909467)
25. de Boer WI, van Schadewijk A, Sont JK, et al. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;158(6):1951-1957. (Pubitemid 29008838)
26. Takizawa H, Tanaka M, Takami K, et al. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstruc tive pulmonary disease(COPD). Am J Respir Crit Care Med. 2001;163(6):1476-1483. (Pubitemid 32506619)
27. Garcia-Cruset S, Carpenter KL, Guardiola F, Stein BK, Mitchinson MJ. Oxysterol profiles of normal human arteries, fatty streaks and advanced lesions. Free Radic Res. 2001;35(1):31-41. (Pubitemid 32725623)
28. Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol. 2000;105(2 pt 1):193-204. (Pubitemid 30109029)
29. Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003;200(4):500-503. (Pubitemid 36818250)
30. Ohta K, Mortenson RL, Clark RA, Hirose N, King TE Jr. Immunohistochemical identification and characterization of smooth muscle-like cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995;152(5 pt 1):1659-1665.
31. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066-1071. (Pubitemid 27163860)
32. Caramori G, Romagnoli M, Casolari P, et al. Nuclear localisation of p65 in sputum macrophages but not in sputum neutrophils during COPD exacerbations. Thorax. 2003;58(4):348-351. (Pubitemid 36411423)
33. Szulakowski P, Crowther AJ, Jiménez LA, et al. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(1):41-50. (Pubitemid 43955243)
34. Rajendrasozhan S, Yang SR, Kinnula VL, Rahman I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(8):861-870. (Pubitemid 351600664)
35. Rahman I, MacNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med. 1996;21(5):669-681. (Pubitemid 26331096)
36. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350-1358. (Pubitemid 30408720)
37. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev. 2004;56(4):515-548. (Pubitemid 39658462)
38. Lee KY, Ho SC, Lin HC, et al. Neutrophil-derived elastase induces TGF-beta1 secretion in human airway smooth muscle via NF-kappaB pathway. Am J Respir Cell Mol Biol. 2006;35(4):407-414.
39. Lee KY, Ito K, Hayashi R, Jazrawi EP, Barnes PJ, Adcock IM. NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGFbeta1 gene transcription. J Immunol. 2006;176(1):603-615. (Pubitemid 43023309)
40. Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med. 2006;12(1):99-106. (Pubitemid 43050083)
41. 2 inhalation technique and mass isotopomer distribution analysis to study oxygenation of cholesterol in rat. Evidence for in vivo formation of 7-oxo-, 7 beta-hydroxy-, 24-hydroxy-, and 25-hydroxycholesterol. J Biol Chem. 1995;270(35):20278-20284.
42. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006;174(8):886-893. (Pubitemid 44564788)